Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
Geary RS, Bradley JD, Watanabe T, Kwon Y, Wedel M, van Lier JJ, VanVliet AA. Geary RS, et al. Among authors: vanvliet aa. Clin Pharmacokinet. 2006;45(8):789-801. doi: 10.2165/00003088-200645080-00003. Clin Pharmacokinet. 2006. PMID: 16884318 Clinical Trial.
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ, Hilhorst M, Van Vliet A, Snyder P, Palfreyman MG, Gawryl M, Dgetluck N, Massaro M, Tiessen R, Timmerman W, Hilt DC. Barbier AJ, et al. Clin Ther. 2015 Feb 1;37(2):311-24. doi: 10.1016/j.clinthera.2014.09.013. Epub 2014 Oct 14. Clin Ther. 2015. PMID: 25438724 Free article. Clinical Trial.
Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ, van Vliet AA, van de Wetering J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Janssen HL, Reesink HW. Bergmann JF, et al. Aliment Pharmacol Ther. 2011 Aug;34(4):443-53. doi: 10.1111/j.1365-2036.2011.04745.x. Epub 2011 Jun 26. Aliment Pharmacol Ther. 2011. PMID: 21707679 Free article. Clinical Trial.
Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A, Liu BS, Groothuismink ZM, Bergmann JF, de Bruijne J, Hotho DM, Hansen BE, van Vliet AA, van de Wetering de Rooij J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Reesink HW, de Knegt RJ, Janssen HL. Boonstra A, et al. Antivir Ther. 2012;17(4):657-67. doi: 10.3851/IMP2023. Epub 2011 Dec 19. Antivir Ther. 2012. PMID: 22301364
Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CM, de Knegt RJ, Komoda Y, van de Wetering de Rooij JJ, van Vliet A, Jansen PL, Molenkamp R, Schinkel J, Reesink H, Janssen HL. de Bruijne J, et al. Antivir Ther. 2010;15(5):765-73. doi: 10.3851/IMP1606. Antivir Ther. 2010. PMID: 20710058 Clinical Trial.
Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW. Hotho DM, et al. Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989. Epub 2011 Nov 30. Antivir Ther. 2012. PMID: 22293533 Clinical Trial.
26 results